<DOC>
	<DOCNO>NCT01396278</DOCNO>
	<brief_summary>The aim study ass compare efficacy safety BI 54903 three different dosage ( b.i.d ) . , fluticasone propionate hydrofluoroalkane ( HFA ) meter dose inhaler ( MDI ) dose 440 mcg b.i.d low dose fluticasone propionate 88 mcg b.i.d . 8-week treatment period asthmatic patient age 12 65 year inadequately control medium dose ICS therapy demonstrate decrease forced expiratory volume one second ( FEV1 ) range 10 25 % asthma control questionnaire-6 ( ACQ-6 ) equal great 1.5 time randomisation .</brief_summary>
	<brief_title>Study BI 54903 ( Inhaled Corticosteroid ) Administered Twice Daily Via Respimat Inhaler Patients With Asthma Inadequately Controlled Medium Dose Inhaled Corticosteroid ( ICS ) .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : 1 . Must willing able give inform consent . 2 . Male female patient age least 12 65 year . 3 . All patient must history asthma diagnose physician least three month time enrolment trial accord 2009 Global Initiative Asthma ( GINA ) Guidelines . The initial diagnosis asthma must make age 40 year . 4 . All patient must maintenance treatment highdose ICS longacting beta 2agonist ( LABA ) , stable least six week prior Visit 1 5 . All patient must prebronchodilator FEV1 le 60 90 % predict normal ACQ6 mean score le 1.5 prescreening Visits 1and 2 . 6 . Patients must neversmokers exsmokers smoke history le 10 packyears smoke cessation least one year prior screen . 7 . Patients must able use Respimat® inhaler MDI correctly 8 . Patients must able perform trialrelated procedure include technically acceptable pulmonary function test electronic peak expiratory flow ( PEF ) measurement , must able maintain record study period require protocol . To enter treatment period follow additional criterion meet : 9 . All patient must improvement FEV1 le 12 % baseline absolute change least 200 mL within 1530 min administration 400 mcg salbutamol/albuterol HFA MDI demonstrate Visit 1 one visit runin period . 10 . During runin period ( clinic visit ) patient must symptomatic ( ACQ6 mean score equal great 1.5 ) show decrease morning prebronchodilator FEV1 le 10 % less equal 25 % prescreening baseline FEV1 Visit 2 . Exclusion criterion : 1 . Patients significant pulmonary disease asthma significant medical condition ( determine medical history , examination clinical investigation screen ) may , opinion investigator , result following : ( ) put patient risk participation trial ( ii ) influence result trial ( iii ) cause concern regard patient´s ability participate trial . 2 . Patients clinically relevant , abnormal screen haematology and/or blood chemistry finding , abnormality indicate significant disease define exclusion criterion . 1 . 3 . Patients history upper respiratory tract infection ( URTI ) low respiratory tract infection ( LRTI ) past four week prior prescreening Visit 1 , prescreening runin period . 4 . Patients exacerbation underlie asthma eight week prior prescreening Visit 1 . 5 . Patients active allergic rhinitis require treatment systemic corticosteroid . 6 . Any following criterion meet prescreening/runin period ( Visits 1 6 ) : clinic prebronchodilator FEV1 % predict less 40 % , 12 puff rescue salbutamol/albuterol HFA MDI per day &gt; 2 consecutive day , exacerbation asthma . 7 . Patients history pneumonectomy plan undergo thoracotomy reason . 8 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program six week prior first screen visit 1 . 9 . Patients two hospitalization asthma within previous 12 month . 10 . Patients recent history myocardial infarction last twelve month know coronary heart disease require treatment 11 . Patients history hospitalisation due heart failure past twelve month 12 . Patients myocarditis unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year 13 . Patients significant alcohol drug abuse opinion investigator within past two year 14 . Patients rheumatoid arthritis systemic disease require immune system modulate treatment 15 . Patients suffer history glaucoma , increase intraocular pressure , and/or cataract 16 . Pregnant nursing woman 17 . Women childbearing potential use highly effective method birth control . 18 . Patients treated antiIgEantibodies ( e.g . omalizumab , Xolair® ) immune system modulate antibody tumor necrosis factoralpha blocker ( TNFalpha blocker ) within six month prior Visit 1 . 19 . Patients treat follow drug past four week prior Visit 1 foreseen need study : Nonselective ßblockers ( topical cardioselective betablocker eye medication nonnarrow angle glaucoma allow ) , Oral systemic corticosteroid , Oral betaagonists , Changes allergen desensitisation therapy last 6 month , Immune system modulate agent methotrexate cyclosporine , Inhibitors cytochrome P450 3A4 antifungal ( e.g . ketoconazole , itraconazole ) , antibiotic ( e.g . erythromycin ) antiretroviral drug . 20 . Patients treat leukotriene modifier , chromones theophylline within two week prior Visit 1 . 21 . Patients treat tiotropium within 3 week prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>